Today’s Food and Drug Administration approval of a supplemental biologics license for the monoclonal antibody omalizumab (Xolair) highlights the vital role of the National Institutes of Health-supported research that underpins the FDA decision.
Clinical Challenges: Navigating New RSV Protections for the Youngest Kids
Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization in the U.S., according to the CDC. But now there are two options —